Issued 2026-08-13 at $13.58 · now $13.97 (2026-08-13, +2.9% since)
Based on its own history, a month from the 2026-08-13 close, SLN has typically landed between $9.62 and $19.80 — a range of −29.2% to +45.8% from the issuance price $13.58.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,469 overlapping 1 month windows · 2020-09-08 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($13.58) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where SLN has typically landed a month from the 2026-08-13 close of $13.58 — the range is history, not a prediction.
- now $13.97 (+2.9%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $13.42 (-1.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $11.58–$15.25
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $9.62–$19.8
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-11-11 | −63.2% | −63.2% | +0.0% |
| 2024-10-22 | −61.5% | −61.5% | +0.4% |
| 2024-10-21 | −61.2% | −61.2% | +0.6% |
| 3 best | |||
| 2023-10-31 | +92.1% | +0.0% | +92.1% |
| 2023-11-17 | +84.1% | +0.0% | +86.4% |
| 2023-10-30 | +83.7% | −4.3% | +83.7% |
1,469 overlapping windows · 2020-09-08 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study to Assess SLN124 in Patients With Polycythemia Vera (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.